Clinical and metabolic response to probiotic administration in people with Parkinson's disease

Background & aims: The investigation was done to assess the impacts of probiotic supplementation on movement and metabolic parameters in individuals with Parkinson's disease (PD).

Methods: The study is randomized, double-blind, placebo-controlled clinical trial, which was done in sixty people with PD. Individuals were randomly divided into two groups in order to take either 8x10CFU/day probiotic or placebo (n=30 each group) that lasted 12 weeks. The Movement Disorders Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) was recorded at pre- and postintervention.

Compared with the placebo, consuming probiotic decreased MDS-UPDRS (-4.8 ± 12.5 vs. 3.8 ± 13.0, P=0.01). Probiotic supplementation also reduced high sensitivity C-reactive protein (1.6 ± 2.5 vs. 0.1 ± 0.3 mg/L, P < 0.001) and malondialdehyde (0.2 ± 0.3 vs. 0.1 ± 0.3 mmol/L,P=0.006), and enhanced glutathione levels (40.1 ± 81.5 vs.12.1 ± 41.7 mmol/L, P=0.03) in comparison with the placebo.Additionally, probiotic consumption resulted in a statistically significant reduction in insulin levels (2.1 ± 3.4 vs. 1.5 ± 5.1 mIU/mL, P=0.002) and insulin resistance (0.5 ± 0.9 vs. 0.4 ± 1.2, P=0.002), and a statistically significant rise in insulin sensitivity (0.01 ± 0.02 vs.0.006 ± 0.02, P=0.01) in comparison with the placebo. Probiotic intake had no any significant impact on other metabolic profiles.

Conclusions: Our study evidenced that 12 weeks of probiotic consumption by individuals with PD had useful impacts on MDS-UPDRS and few metabolic profiles.



Probiotic, Parkinson's disease, Movement disorders, Inflammation, Oxidative stress